Healthcare sector steady EPS growth at 7% annually, with biotech valuations down 20% from highs, may provide asymmetric upside. A value investing program could deploy capital into undervalued clinical pipeline plays. Myth: I often hear Booth described as a “finance school” or a “quant school.” As the firm has evolved, its commitment to disciplined, value-oriented investment principles has continued to anchor its philosophy and reward its stakeholders. The firm is 100% employee-owned. Consumer staples show resilient earnings; forward dividend payout ratios stand under 55%, which may offer sustainable yield opportunities under a value investing program seeking defensive long-term plays.